1800 202 8726
Understanding your pathology report

Luminal A, Luminal B and — Molecular Subtypes Explained

When your breast cancer report uses words like Luminal A, Luminal B, HER2-enriched or Triple-negative, it is placing your tumour into one of four categories your oncologist uses to guide treatment. Those categories come from combining four marker results already in your report.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026

  • Four markers, four subtypes — ER, PR, HER2 and Ki-67 are combined to place your tumour into one of four molecular categories.
  • Luminal A tends to grow slowly — It is hormone-sensitive and generally associated with a more gradual course than the other subtypes.
  • Luminal B is also hormone-sensitive — It grows faster than Luminal A, which often changes what additional treatment your oncologist considers.
  • Subtype shapes the treatment plan — Your oncologist uses the subtype alongside stage, grade and your overall health to build your plan.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Luminal A and Luminal B are two of four breast cancer molecular subtypes, determined by combining your ER, PR, HER2 and Ki-67 marker results. The subtype tells your oncologist how the cancer is likely to behave and which treatments are most likely to work. Your pathology report contains all four results.

What do Luminal A and Luminal B mean on a breast cancer report?

Breast cancer is not one disease. Pathologists divide it into four molecular subtypes based on which proteins the tumour cells carry on their surface and how fast those cells are dividing.

The four markers tested on your biopsy — ER, PR, HER2 and Ki-67 — are combined to assign a subtype. That assignment tells your oncologist something the tumour grade and size alone cannot: how the cancer is likely to respond to different types of treatment.

Luminal A and Luminal B together make up the majority of breast cancer diagnoses. Both are oestrogen-driven. The difference between them is mainly in how fast the cells are dividing, which is what Ki-67 measures.

How do the four subtypes compare?

SubtypeER / PRHER2Ki-67Typical behaviour
Luminal APositiveNegativeLowSlow-growing; tends to respond well to hormone-directed treatment
Luminal B (HER2-negative)PositiveNegativeHighFaster-growing; may need additional treatment alongside hormone-directed therapy
Luminal B (HER2-positive)PositivePositiveOften highResponds to both hormone-directed and HER2-targeted treatment
HER2-enrichedNegativePositiveOften highDriven by HER2, not hormones; responds to HER2-targeted treatment
Triple-negativeNegativeNegativeOften highNo hormone or HER2 target; a different treatment approach applies

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What each marker measures

ER (Oestrogen Receptor)
Measures whether cancer cells have receptors that bind to oestrogen. A positive result means oestrogen may be fuelling the cancer's growth — and that treatments which lower or block oestrogen may help.
PR (Progesterone Receptor)
Measures sensitivity to progesterone. It is usually positive when ER is positive and tends to confirm the hormone-driven nature of the tumour.
HER2 (Human Epidermal Growth Factor Receptor 2)
A protein on cancer cells that promotes growth. When overexpressed, it makes the tumour more aggressive — but also makes it a specific target for HER2-directed treatment.
Ki-67
Measures what proportion of cancer cells are actively dividing. A low score suggests slow growth; a high score suggests faster division. Ki-67 is what mainly separates Luminal A from Luminal B when ER and HER2 look similar.

Did you know?

The cut-off used to separate a 'low' from a 'high' Ki-67 score is not standardised across all laboratories. A score that reads as borderline in one centre may be classified differently in another — which is why your oncologist interprets Ki-67 as part of the full picture, not on its own.

Source: St. Gallen International Consensus Expert Panel on the Primary Therapy of Early Breast Cancer

Questions families ask about subtype results

My report says Luminal A — is that reassuring?

Luminal A is generally associated with slower growth and a good response to hormone-directed treatment, which is why it is often described as the most favourable subtype. That said, subtype is not stage. A Luminal A tumour that is large or has spread to lymph nodes still requires careful treatment planning. Your oncologist uses the subtype as one input alongside stage, grade and your overall health — not as a standalone verdict.

What is the difference between Luminal B HER2-negative and HER2-positive?

Both are hormone-positive and faster-growing than Luminal A. The HER2-negative variant is driven mainly by hormones and rapid cell division. The HER2-positive variant adds overexpression of the HER2 protein, giving your oncologist two potential treatment targets rather than one. The HER2-positive variant is generally considered to need more active treatment. Your oncologist will tell you which applies to you and what it means for your plan.

My report lists ER, PR, HER2 and Ki-67 but does not say 'Luminal' anywhere — is something missing?

No. Most Indian pathology reports list the individual marker results rather than assigning a subtype label. 'Luminal A' or 'Luminal B' is clinical shorthand your oncologist derives from those four numbers. You need all four results clearly stated, not the label itself. If any marker is listed as 'not done', ask whether it can be added from the same biopsy block before your treatment planning begins.

Can the subtype result change after treatment starts?

The subtype measured on your biopsy reflects the tumour at diagnosis. If you receive treatment before surgery — for instance, chemotherapy given first to shrink the tumour — the cells that survive may show different marker levels on the surgical specimen, and your team will usually re-test at that point. If surgery came first, the biopsy result stands as the basis for your ongoing treatment plan.

Does a triple-negative result mean there are no treatment options?

No. Triple-negative means no oestrogen receptor, no progesterone receptor and no HER2 overexpression — so three specific targets are absent, ruling out hormone-directed and HER2-targeted treatments. Other options remain, and the field is moving steadily. What matters for you is your stage and your specific results, not a general population pattern. Your oncologist will explain which approach is recommended for your case.

Explore 112 more Markers, Molecular Testing and Test Accuracy topics

HUB — How Accurate Is a Biopsy? Repeats, Errors and Second Opinions

HUB — IHC and Molecular Markers on a Biopsy

HUB — Labs, Slides and Second Opinions on a Biopsy

All Markers, Molecular Testing and Test Accuracy →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

What is the difference between Luminal A and Luminal B?

Both subtypes are oestrogen-positive, meaning the cancer is sensitive to oestrogen. The main difference is Ki-67 — a measure of how fast cells are dividing. Luminal A has a low Ki-67, indicating slower growth. Luminal B has a higher Ki-67, indicating faster growth. When HER2 is also positive, the cancer falls into the Luminal B HER2-positive group, which adds another characteristic your oncologist will plan around.

What does ER-positive mean on my report?

ER-positive means oestrogen is likely fuelling your cancer's growth. It also means the cancer may respond to treatments that lower oestrogen levels or block oestrogen from reaching cancer cells. Your oncologist will explain which approach suits your subtype, stage and overall health. ER-positive is also why Luminal subtypes tend to have more treatment options available than ER-negative ones.

Is a high Ki-67 score serious?

A high Ki-67 means more cancer cells are dividing at any given moment, which generally indicates faster growth. It is one of the things that shifts a cancer from Luminal A into the Luminal B category. Faster-growing cancers sometimes require more active treatment, but Ki-67 is interpreted alongside your other markers and your stage — not on its own. Ask your oncologist what your specific result means given your overall picture.

Can two people with the same subtype have different treatment plans?

Yes, and this is common. The subtype is one input into the treatment decision, not the whole answer. Two people both diagnosed with Luminal B may have different stages, different tumour sizes and different numbers of lymph nodes involved. All of those factors shape the final plan. The subtype narrows the range of treatments most likely to work; it does not produce a single standard answer for every person.

What if only some of my four markers have been tested?

All four markers — ER, PR, HER2 and Ki-67 — are needed to assign a subtype accurately. If any is missing, ask your oncologist whether it can be added from the original biopsy block before treatment planning is finalised. In most cases the same tissue block is used, so a new biopsy is not needed. An incomplete marker set can leave your oncologist working with an incomplete picture of how your cancer is likely to behave.

Should I ask for a second opinion on my subtype result?

A second opinion on the pathology is reasonable when markers are borderline, the report is incomplete or you want confirmation before a major treatment decision. Bring your original biopsy block or slides — a second opinion re-tests on the same tissue and usually does not need a new biopsy. Your treating oncologist should support this request. CION centres coordinate second-opinion pathology review for patients who need it.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation